Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Urinary Tract Infections Growing resistance rates bring opportunities for both new and old drugs

Stakeholder Opinions: Urinary Tract Infections Growing resistance rates bring opportunities for both new and old drugs

Urinary tract infections (UTIs) include infections of the kidneys, ureters, and bladder. Escherichia coli is the major UTI pathogen, with emerging extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly difficult to treat. Bacterial resistance to the most commonly used UTI drugs is growing, highlighting the unmet need and opportunity for novel therapies.

Disease background, segmentation and epidemiology of UTIs in the US, Japan and five major European countries

Overview of unmet needs, current clinical practice, guidelines and adherence

Discussion of trends in incidence of major pathogens and therapies as well as resistance rates

Outline of diagnosis, treatment and referral patterns

UTIs are a major driver of ambulatory care utilization. US statistics point to more than 10 million visits to ambulatory care settings for UTIs per year. From 1995 to 2006, the incidence of cystitis and UTI in unspecified sites in the US increased by 10.7%.

Bacterial resistance is the most important factor affecting UTI treatment options and varies both nationally and locally. Resistance rates as low as 10% are deemed to be of concern with regards to efficacy of empiric therapy. Levels of resistance to some older drugs may reach 40-50% in some areas, rendering these drugs ineffective.

Two old drugs, nitrofurantoin and fosfomycin, have remarkably favorable resistance profiles and good efficacy for the treatment of cystitis, and therefore may provide highly useful future treatment options. Given these compounds' age, they are not widely prescribed, requiring physician education to improve familiarity and improve their uptake.

Learn about the significance of UTIs as a an indication for antibacterial compounds

Understand and capitalize on clinical unmet needs in the market through new product development in therapy and diagnosis

Discover optimal ways to communicate with physicians by supporting efforts to address gaps in diagnosis, treatment and guideline adherence

Publication: 39904
Library Code: DMHC2495
Type: Report
Format: PDF
Pages: 126

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions